<DOC>
	<DOCNO>NCT01211834</DOCNO>
	<brief_summary>The purpose study assess efficacy safety tocilizumab v placebo , combination stable , ongoing therapy , regard reduction sign symptoms patient moderate severe active RA inadequate response current DMARD treatment</brief_summary>
	<brief_title>Efficacy Safety Tocilizumab Combination With DMARDs Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient , &gt; = 18 year age Active RA &gt; 6monts duration Received permit DMARDs stable dose least 8 week Rheumatic autoimmune disease RA Significant systemic involvement secondary RA ALT AST &gt; ULNâ…¹1.5 Platelet count &lt; 100,000/mm3 Hemoglobin &lt; 8.5 g/dL White blood cell &lt; 3,000/mm3 Absolute neutrophil count &lt; 2,000/mm3 Absolute lymphocyte count &lt; 500/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>